Activists and CoronavirusFunds will target devalued firms after crisis 05 May 2020
Angharad Carrick at CityAM writes an extensive story on the activism landscape in light of coronavirus. Much has been made of the comparison between the coronavirus crisis and the global financial crash over a decade ago.The pandemic has left dozens of listed UK companies in need of a lifeline, with the travel and leisure sectors devastated by government-imposed restrictions.
FTSE firms across all sectors have witnessed their stocks implode as the coronavirus lockdown has forced them to furlough staff. The question now facing many boards is whether – as happened in 2008 – hedge funds and other activist investors will begin circling these distressed companies. However, despite widespread fears of opportunistic actions, activists are biding their time – for now.
There is a general consensus that activists will not begin campaigns in the midst of the pandemic, despite a crash in valuations. In part this is down to an awareness among activists that new campaigns would generate a large degree of scepticism. Ali Saribas comments: “I don’t think there’s a market for it. Activists know there would be some kind of scepticism. Adding another complicating factor when a company is in survival mode may not necessarily be the right timing for this type of campaign.” Activists cannot enact change by themselves and need to win over other investors to support their campaigns.
You can access the full article following this link (no subscription required).
Activist investors are expected to launch more and bolder campaigns for change among European companies in the year ahead, advisers told Reuters, after a record number in 2023.
AQTION, a subsidiary of SquareWell Partners, published its inaugural study – ‘Stewardship in AQTION’ – which details how the world’s largest 65 asset managers and owners steward their portfolio companies and how they incorporate extra-financial considerations into their investment decision-making processes.
Carl Icahn is preparing for a second board battle at gene-sequencing company Illumina after shareholders elected his candidate, Andrew Teno, to the company’s board and ousted the chairman, John Thompson, in May. Icahn then successfully pushed out former CEO Frances DeSouza in June.